Sanofi and MannKind Announce Global Licensing Agreement for Afrezza(R) (insulin human) Rapid-Acting Inhaled Insulin

August 11th, 2014 Sanofi and MannKind Corporation MNKD announced today that they have entered into a worldwide exclusive licensing agreement for development and commercialization of Afrezza® (insulin human) Inhalation Powder, a new rapid-acting inhaled insulin therapy for adults with type 1 and type 2 diabetes. The companies plan to launch Afrezza in the United States in the first quarter of 2015. Under the collaboration …

First Dengue Vaccine Candidate to Show Efficacy Against Dengue Fever and Dengue Haemorrhagic Fever in Asia

88.5% reduction of Dengue Haemorrhagic Fever shown in detailed analyses of world’s first phase III efficacy study published in The Lancet – Two thirds reduction in hospitalization observed Favorable safety profile is consistent with safety documented in previous studies July 11, 2014 Sanofi Pasteur, the vaccines division of Sanofi, today announced the publication in The Lancet of the detailed results …

Sanofi Pasteur Announces FDA Has Expanded Age Indication of Adacel® Tdap Vaccine to Include Persons 10 Years of Age

Approval reinforces the safety profile of Adacel as an active booster immunization for the prevention of tetanus, diphtheria, and pertussis April 1, 2014 Sanofi Pasteur, the vaccines division of Sanofi, announced today that the U.S. Food and Drug Administration (FDA) has expanded the approved age indication of Adacel® (Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed; Tdap) for active …

Will Sanofi’s dengue vaccine come in time for Brazil Olympics?

Sanofi has been proudly showing reporters round its new facility in France, as it bravely fires up production of its dengue vaccine ahead of late-stage clinical trial results and regulatory approval. Starting vaccine production early is a bold move, especially following the perplexing results with the vaccine in Thailand last year (the vaccine conferred protection against just three of the …

Sanofi plans China growth with 4 new plants

Sanofi plans to open four manufacturing plants this year in China, reports the Wall Street Journal. The WSJ reports that Sanofi expects to see "double-digit sales growth" in the next five years in China, and plans to expand its animal health and vaccine business in the country. The French pharmaceutical company currently has six plants in China, but the addition …

The Top 5 Vaccine Companies by Revenue in 2012

The top 5 vaccine companies captured more than 90% of vaccine sales in 2012, report FierceVaccines. Using figures from EvaluatePharma, these are the Top 5 vaccine companies by revenue in 2012: 1. Sanofi Manufacturers of the PENT Act-HIB (DTPw, Hib & polio) vaccine – one of the top-selling vaccines that generated $1.5b in 2012. 2. Merck Manufacturers of big-seller Gardasil, …

Sanofi’s 6-in-1 paediatric shot Hexyon recommended for market approval

Sanofi Pasteur have announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has recommended market approval for their 6-in-1 paediatric vaccine Hexyon/Hexacima. The vaccine would be marketed as Hexyon in Western Europe, where it is a joint venture between Sanofi Pasteur and Merck & Co, and Hexacima in Eastern Europe, where it …